Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Completed Phase 1 Interventional

An fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism

NCT00263796
View directory record Official record
Conditions
Autism
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Anagnostou, Evdokia, M.D.
Individual
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Oct 14, 2026, 9:53 PM EDT
Active, not recruiting Phase 3 Interventional

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

NCT04468659
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Interventions
Lecanemab, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430

NCT03800173
View directory record Official record
Conditions
Marburg Virus Disease
Interventions
galidesivir, placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH

NCT00159861
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
16 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
33
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

NCT01002742
View directory record Official record
Conditions
Graft-versus-Host Disease, Immune System Disorders
Interventions
Mycophenolate Mofetil, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
36
States / cities
Duarte, California • La Jolla, California • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 14, 2026, 9:53 PM EDT
Terminated Phase 3 Interventional

Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis

NCT04707703
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2, Aspergillosis Invasive
Interventions
Isavuconazonium Injection [Cresemba], Placebo
Drug
Lead sponsor
Jeffrey Jenks, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Orange, California • Sacramento, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 14, 2026, 9:53 PM EDT
Terminated Phase 1Phase 2 Interventional

Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing

NCT03117166
View directory record Official record
Conditions
Pain
Interventions
lidocaine, Placebo
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

American Trial Using Tranexamic Acid in Thrombocytopenia

NCT02578901
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE

NCT03312907
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
28
States / cities
Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

NCT03635567
View directory record Official record
Conditions
Cervical Cancer
Interventions
Pembrolizumab, Paclitaxel, Cisplatin, Carboplatin, Bevacizumab, Placebo to pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
20
States / cities
Anchorage, Alaska • Phoenix, Arizona • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 2 Interventional

Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease

NCT01850381
View directory record Official record
Conditions
Parkinson's Disease
Interventions
GM608, Placebo Comparator
Drug
Lead sponsor
Genervon Biopharmaceuticals, LLC
Industry
Eligibility
30 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 14, 2026, 9:53 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND)
Biological · Other · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Varenicline and Nicotine Interactions in Humans (VA)

NCT00606892
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline, Placebo, IV Nic
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

NCT02066402
View directory record Official record
Conditions
Bacterial Infections
Interventions
Tedizolid (BAY119-2631), Placebo Tedizolid (BAY119-2631), Linezolid, Placebo Linezolid
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Chula Vista, California • La Mesa, California • Oceanside, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 14, 2026, 9:53 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

NCT03866577
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
Biological: M254, Placebo, Intravenous immunoglobulin (IVIg)
Biological · Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Whittier, California • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

NCT01576328
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mesenchymal Precursor Cells (MPCs)
Drug
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Garden Grove, California • Miami, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

NCT02287467
View directory record Official record
Conditions
Influenza A, Influenza B
Interventions
Intravenous hyperimmune immunoglobulin (IVIG), Placebo for IVIG
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
San Diego, California • Denver, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 14, 2026, 9:53 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The RECAP2 Study: Midazolam and Psilocybin

NCT06692192
View directory record Official record
Conditions
Psilocybin
Interventions
Psilocybin, Midazolam, Saline
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

NCT03464136
View directory record Official record
Conditions
Crohn Disease
Interventions
Placebo for Ustekinumab, Placebo for Adalimumab, Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg)
Biological
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
67
States / cities
Mobile, Alabama • San Diego, California • Colorado Springs, Colorado + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 2 Interventional

Dose-Response of Adenosine for Perioperative Pain

NCT00298636
View directory record Official record
Conditions
Perioperative Pain
Interventions
adenosine
Drug
Lead sponsor
Xsira Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2006 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)

NCT00895830
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
APD405, Placebo
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
San Francisco, California • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 2 Interventional

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

NCT04918719
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Acetylcysteine, Dextrose in Water
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 3 Interventional

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1

NCT05832931
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Interventions
PLS240, Placebo, Open-Label Extension PLS240
Drug
Lead sponsor
Pathalys Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
49
States / cities
Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 14, 2026, 9:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects

NCT01918995
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2013 · Synced Oct 14, 2026, 9:53 PM EDT